After in vivo LCMV infection, which is probably the most testing challenge, the presence of gene-corrected CD8 T cells was able to prevent HLH onset, as demonstrated not only by cytokine and cellular profiles but also more importantly by clinical and survival outcome measures. The gene discussed is CD8A; the disease is hemophagocytic syndrome.